| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 79,870 | 81,060 | 71,330 | 48,960 | 27,640 |
| Sales Growth | -1.47% | +13.64% | +45.69% | +77.13% | unch |
| Net Income | -51,510 | -55,550 | -86,240 | -62,960 | -34,690 |
| Net Income Growth | +7.27% | +35.59% | -36.98% | -81.49% | unch |
Sight Sciences Inc (SGHT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sight Sciences Inc. is a medical device company. It focused on the development and commercialization of proprietary devises which target the underlying causes of prevalent eye diseases. Sight Sciences Inc. is based in MENLO PARK, Calif.
Fiscal Year End Date: 12/31